Document Detail


Treatment of venous thromboembolism during pregnancy.
MedLine Citation:
PMID:  19217476     Owner:  NLM     Status:  MEDLINE    
Abstract/OtherAbstract:
BACKGROUND: Acute VTE occurs with an incidence of 1-2/1,000 during pregnancy and is associated with an acute mortality of 1-2%. However, data on VTE treatment during pregnancy are sparse: Even though 50 cases occur daily in the EU and US, a recent review identified only 174 cases in the literature.
ACUTE TREATMENT: Standard treatment is LMWH at therapeutic doses or APTT-adjusted UFH. LMWH is at least as safe and effective as UFH in non-pregnant patients. In pregnancy, LMWH is the preferred option, because it offers better bioavailability, fewer injections, superior safety regarding HIT and osteoporosis. LONG-TERM TREATMENT: VKA are contraindicated because of teratogenicity and thus heparin is used for secondary prevention. Since UFH requires therapeutic doses throughout pregnancy, carrying the risk of osteoporosis, LMWH is the drug of choice. In a recent review most patients were treated initially with LMWH, predominately with twice daily injections. Recurrent VTE occurred in 1.2%, bleeding in 1.7%, with no HIT. Whether the long-term dose of LMWH can be reduced remains unresolved: Intermediate dose LMWH has been used effectively in cancer patients, who - like pregnant women - continue to have a high pro-thrombotic burden after the initial phase.
CONCLUSION: Even though acute VTE is not uncommon and represents a life-threatening event during pregnancy, data are sparse, and prospective trial data are needed to answer open questions concerning treatment modalities. Nevertheless, it is evident that LMWH is the preferred option for treatment of VTE during pregnancy.
Authors:
Rupert M Bauersachs
Related Documents :
16154846 - The association between hereditary thrombophilias and pregnancy loss.
19025596 - The impact of close surveillance on pregnancy outcome among women with a prior history ...
22373726 - Increased risk of miscarriage and ectopic pregnancy among women with irritable bowel sy...
21575806 - Clinical management of the short cervix.
23613006 - An exploratory analysis of the utility of adding cardiorespiratory biofeedback in the s...
17713776 - Acute promyelocytic leukemia: an unusual cause showing prolonged disseminated intravasc...
Publication Detail:
Type:  Journal Article; Research Support, Non-U.S. Gov't    
Journal Detail:
Title:  Thrombosis research     Volume:  123 Suppl 2     ISSN:  0049-3848     ISO Abbreviation:  Thromb. Res.     Publication Date:  2009  
Date Detail:
Created Date:  2009-02-16     Completed Date:  2009-05-15     Revised Date:  2013-07-15    
Medline Journal Info:
Nlm Unique ID:  0326377     Medline TA:  Thromb Res     Country:  United States    
Other Details:
Languages:  eng     Pagination:  S45-50     Citation Subset:  IM    
Affiliation:
Medical Department IV, Klinikum Darmstadt, Darmstadt, Germany. bauersachs@em.uni-frankfurt.de
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Descriptor/Qualifier:
Anticoagulants / administration & dosage*
Female
Heparin, Low-Molecular-Weight / administration & dosage
Humans
Pregnancy
Pregnancy Complications, Hematologic / drug therapy*
Venous Thromboembolism / drug therapy*
Chemical
Reg. No./Substance:
0/Anticoagulants; 0/Heparin, Low-Molecular-Weight

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine


Previous Document:  Diagnostic issues of VTE in pregnancy.
Next Document:  Novel approaches in management of immune thrombocytopenia.